TABLE 1.
Correlations between change from baseline in NPS and change in local and systemic type 2 biomarker levels following dupilumab treatment in subgroups of patients with asthma, NSAID‐ERD, prior surgery, or SCS use within the previous 2 years (pooled ITT population)
| Pearson correlation for change in NPS | ||||||||
|---|---|---|---|---|---|---|---|---|
| Correlation coefficient (n) a | ||||||||
| Biomarker | Asthma | Without asthma | NSAID‐ERD | Without NSAID‐ERD | Prior surgery | Without prior surgery | SCS use in previous 2 y | Without SCS use in previous 2 y |
| (n = 258) | (n = 180) | (n = 122) | (n = 316) | (n = 272) | (n = 166) | (n = 329) | (n = 109) | |
| Nasal secretion (week 24) b | ||||||||
| IL‐5 | 0.2241 (42) | 0.3500 (37) | 0.2177 (20) | 0.3135 (59) | 0.3232 (46) | 0.2205 (33) | 0.2873 (67) | 0.1400 (12) |
| Periostin | 0.1536 (43) | 0.2825 (36) | 0.2114 (20) | 0.2579 (59) | 0.2960 (46) | 0.0899 (33) | 0.2362 (68) | 0.1357 (11) |
| Eotaxin‐3 | 0.4575 (26) | 0.2628 (24) | 0.3268 (13) | 0.2808 (37) | 0.2711 (31) | 0.2653 (19) | 0.2457 (42) | 0.6938 (8) |
| Serum (week 52) | ||||||||
| Periostin | 0.0891 (157) | 0.2476 (100) | 0.1036 (69) | 0.1796 (188) | 0.0777 (151) | 0.2855 (106) | 0.1971 (206) | 0.1084 (51) |
| Eotaxin‐3 | 0.0880 (165) | 0.1341 (103) | 0.1684 (71) | 0.0948 (197) | 0.0466 (155) | 0.1463 (113) | 0.1164 (218) | 0.1886 (50) |
| Total IgE | 0.0695 (168) | −0.0491 (104) | −0.1753 (73) | 0.0773 (199) | 0.0450 (159) | −0.0064 (113) | 0.0274 (221) | 0.0512 (51) |
| TARC | 0.0329 (165) | 0.0870 (105) | −0.0084 (72) | 0.0901 (198) | 0.0168 (157) | 0.0993 (113) | 0.1043 (219) | −0.0512 (51) |
| Urine (week 52) | ||||||||
| LTE4 | 0.0425 (166) | 0.2342 (105) | −0.0346 (72) | 0.2133 (199) | 0.1426 (158) | 0.0836 (113) | 0.0980 (219) | 0.3180 (52) |
Abbreviations: IL, interleukin; IT, intent‐to‐treat; LTE4, leukotriene E4; NPS, nasal polyp score; NSAID‐ERD, nonsteroidal anti‐inflammatory drug‐exacerbated respiratory disease; SCS, systemic corticosteroid; TARC, thymus activation‐regulated chemokine; y, years.
a
The number in parentheses is the number of patients with available data for biomarker assessment.
b
SINUS‐52 (Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps) only.